REGULATORY
MHLW OKs Opdivo’s Add’l Indications and Flat Dose, 1st-Line Tagrisso Use and More
The Ministry of Health, Labor and Welfare (MHLW) approved a series of new indications on August 21, including a label expansion and dosage change for Opdivo (nivolumab), as well as the first-line use of Tagrisso (osimertinib) in non-small cell lung…
To read the full story
Related Article
- MHLW Panel Backs Lilly’s Ibrance Contender Abemaciclib for Breast Cancer
August 6, 2018
- Boehringer’s DPP-4/SGLT2 Combo Clears MHLW Panel
July 30, 2018
REGULATORY
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
- Yaz, Actemra Indications Deemed High-Need by MHLW Panel
September 7, 2026
- Minister Defends Scope of Low-Income Exemption for OTC-Like Drug Charge
September 7, 2026
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





